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Summary
We recently found that MLL-rearranged acute lymphoblastic leukemias (MLL) have a unique gene expression profile
including high level expression of the receptor tyrosine kinase FLT3. We hypothesized that FLT3 might be a therapeutic
target in MLL and found that 5 of 30 MLLs contain mutations in the activation loop of FLT3 that result in constitutive
activation. Three are a newly described deletion of I836 and the others are D835 mutations. The recently described FLT3
inhibitor PKC412 proved cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation. PKC412 is
also differentially cytotoxic to leukemia cells with MLL translocations and FLT3 that is activated by either overexpression
of the wild-type receptor or mutation. Finally, we developed a mouse model of MLL and used bioluminescent imaging to
determine that PKC412 is active against MLL in vivo.
Introduction highly specific targets may prove more effective and perhaps
less toxic than conventional chemotherapy.
Gene expression profiles of neoplastic cells are beginning to The identification of non-random chromosomal transloca-
provide important biological and clinical insights. Recent analy- tions in leukemia provides a prominent example of how molecu-
ses of multiple different cancers have identified gene expression lar characterization of cancer can lead to a better understanding
differences between tumors with similar histologic characteris- of tumorigenesis and new therapeutic approaches (Rowley,
1998). Children diagnosed with acute lymphoblastic leukemiatics yet heterogeneous clinical behavior (Alizadeh et al., 2000;
Armstrong et al., 2002; Bhattacharjee et al., 2001; Perou et al., (ALL) that harbors a t(9;22), and those with rearrangements of
the Mixed Lineage Leukemia (MLL) gene on chromosome2000; Singh et al., 2002; Yeoh et al., 2002). Also, retrospective
studies have demonstrated the potential for gene expression 11q23, have a significantly worse prognosis than other patients
with ALL (Chen et al., 1993; Pui et al., 1990, 1991). This knowl-based prediction of response to therapy (Pomeroy et al., 2002;
Shipp et al., 2002; van’t Veer et al., 2002). These studies provide edge prompted the development of a tailored chemotherapeutic
approach for patients with ALL harboring a t(9;22) (Arico etevidence that tumor-intrinsic biological heterogeneity is at least
partly responsible for the differing clinical responses to therapy al., 2000). More importantly, the detailed understanding of the
molecular mechanisms of the BCR-ABL tyrosine kinase en-and suggest that a refined molecular classification of cancer
will lead to the development of tailored therapeutic regimens. coded by the t(9;22) has resulted in the development of an
oncogene-targeted therapy using the tyrosine kinase inhibitorThe most exciting, and yet unrealized, promise of cancer geno-
mics is the identification of new, unanticipated therapeutic tar- STI571 (Druker et al., 2001a). While the protein products of other
chromosomal translocations also represent rational targets,gets. Development of therapeutic strategies directed toward
S I G N I F I C A N C E
Gene expression profiles of cancer cells promise to more accurately define diseases, predict response to therapy, and ultimately
identify new therapeutic targets. Recent gene expression studies of leukemias have shown that recurrent chromosomal translocations
found in leukemic cells specify unique diseases. This provides the opportunity to test specifically expressed proteins as new therapeutic
targets in these diseases. FLT3 is highly expressed in MLL-rearranged acute lymphoblastic leukemias (MLL) compared to other acute
leukemias. Here, we validate FLT3 as a therapeutic target in MLL and show that FLT3 inhibitors are active against a mouse model of the
disease. This represents the validation of a therapeutic target identified by gene expression analysis and mandates the development of
clinical trials of FLT3 inhibitors in this chemotherapy-resistant leukemia.
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most encode DNA binding proteins which have proven difficult Table 1. FLT3 mutations in MLL
to inhibit with small molecules. Therefore, identification of new
Mutation N Amino acid change % Totaltherapeutic targets in leukemia is of utmost importance.
CAT-del 3 Ile836-Del 10We recently demonstrated that lymphoblastic leukemias
GAT-TAT 1 Asp835-Tyr 3with rearrangement of the MLL gene display a remarkably con-
GAT-CAT 1 Asp835-His 3
sistent and unique gene expression profile that distinguishes
Thirty MLL samples were analyzed for the presence of activation loop muta-them from either ALL or acute myelogenous leukemia (AML)
tions in FLT3 by RT-PCR as described (Yamamoto et al., 2001).(Armstrong et al., 2002). Based on this finding, we proposed
that they be considered a unique leukemia called MLL. Another
recent gene expression study of large numbers of cases pro-
vided support for the hypothesis that distinct leukemias are
tandem duplications (FLT3-ITDs) are not found in MLL samplesspecified by each of the unique chromosomal abnormalities
(Xu et al., 2000), thus we looked for the presence of activationfound in lymphoblastic leukemias (Yeoh et al., 2002). Our ex-
loop mutations. Of the 30 primary MLL samples tested, 5 hadpression profile of MLL suggests that it is arrested at an early
point mutations in the FLT3 activation loop (Table 1). Three ofstage of hematopoietic development, perhaps soon after the
the leukemias had a 3 nucleotide deletion that leads to a deletioncommon lymphoid progenitor stage. Of particular interest is that
of Isoleucine 836 (836). Two of the leukemias had mutationsthe receptor tyrosine kinase FLT3 was the gene most consis-
that result in an amino acid change from Aspartic Acid 835 totently overexpressed in MLL as compared to other acute leuke-
either Tyrosine or Histidine (D835Y or D835H) (Table 1). Wemias (Armstrong et al., 2002).
have examined two of the samples bearing FLT3 mutations andFLT3 is a class III receptor tyrosine kinase that shares struc-
noted comparably high levels of expression as in MLL samplestural similarity with C-FMS, C-KIT, and PDGFR (Matthews et
with wild-type FLT3.al., 1991; Rosnet et al., 1991; Small et al., 1994). Gene ablation
The D835Y and D835H mutations have been shown to leadexperiments have established that FLT3 plays an important role
to constitutive activation of FLT3 (Yamamoto et al., 2001), butin early hematopoietic development (Mackarehtschian et al.,
the 836 is a newly described mutation. We therefore deter-1995). Recent studies have shown that FLT3 is mutated and
mined if the deletion of isoleucine 836 leads to constitutiveconstitutively active in approximately 30% of cases of AML
activation of the FLT3 kinase. Expression of an active receptor(Gilliland and Griffin, 2002). The most common mutation results
tyrosine kinase in the IL3-dependent murine lymphocyte cellin an in-frame duplication of short sequences present in the
line Ba/F3 renders the cells IL3 independent (Weisberg et al.,juxtamembrane region of the receptor (Nakao et al., 1996). This
2002). When expressed in Ba/F3 cells, both D835Y-FLT3 andleads to receptor dimerization and activation in the absence of
836-FLT3 molecules contained an increased phosphotyrosinethe FLT3 ligand (FLT3L) (Kiyoi et al., 2002). The second type of
content as compared to the wild-type FLT3 (Figure 1A). Expres-mutation affects either aspartic acid 835 or isoleucine 836 in
sion of FLT3 with either the D835Y or the 836 mutation ren-the receptor activation loop (Yamamoto et al., 2001). Since the
dered Ba/F3 cells IL3 independent whereas expression of theactivation loop has autoinhibitory activity, mutation of this region
wild-type FLT3 did not lead to IL3-independent growth. (Figurelikely results in a conformational change that leads to constitu-
1B). Thus at least 16% of MLL samples contain activating muta-tive receptor activity. The presence of these mutations, along
tions, providing supporting evidence for FLT3 as a new thera-with the development of FLT3 inhibitors, has generated much
peutic target in this leukemia.interest in FLT3 as a new therapeutic target (Gilliland and Griffin,
2002). While FLT3 is the most commonly mutated gene in AML,
Activated FLT3 present in MLL is inhibited by PKC412activating mutations of FLT3 are not common (5%) in acute
The presence of FLT3 activating mutations in MLL suggestslymphoblastic leukemias (ALL) (Yamamoto et al., 2001).
that inhibition of FLT3 will be a new therapeutic avenue in thisGiven the high level expression of FLT3 in MLL, and its early
disease. A number of small molecule FLT3 inhibitors with differ-hematopoietic gene expression profile, we hypothesized that a
ential activities toward wild-type and mutated FLT3 have re-constitutive FLT3 signal might be involved in the development
cently been described (Kelly et al., 2002; Levis et al., 2002;and maintenance of MLL. If so, this would not only provide a
Weisberg et al., 2002; Yee et al., 2002). Because some mole-new avenue for therapy in MLL, but also validate the use of
cules do not inhibit all of the FLT3 mutants, it is critical that thegene expression analysis as a method to identify both unique
inhibitors be tested against all new mutations. PKC412diseases and new therapeutic targets for those diseases. Here
(N-benzoyl staurosporine) is a potent inhibitor of wild-type andwe show that MLL lymphoblasts contain activating mutations
mutant FLT3 that posses the FLT3-ITD or the D835Y mutationof FLT3. Furthermore, we have developed a murine model sys-
(Weisberg et al., 2002). We treated Ba/F3 cells rendered IL3tem of MLL and used bioluminescent imaging to show that a
independent by expression of FLT3 containing the D835Y andsmall molecule inhibitor of FLT3 effectively treats the disease
836 mutations with increasing concentrations of PKC412 andin vivo. These data mandate the development of human clinical
assessed for metabolically active cells 48 hr after addition. Bothtrials testing FLT3 inhibitors in this therapy-resistant leukemia.
cell lines were sensitive to PKC412 with 50% inhibition achieved
at 20 nM (Figures 2A and 2B). The same cell lines and Ba/F3Results
cells expressing wild-type FLT3 growing in the presence of IL3
were unaffected by PKC412 at concentrations up to 500 nMFLT3 mutations are present in MLL
Given the consistently high expression of FLT3 in MLL, we (Figures 2A and 2B). In order to determine if the decrease in
cell metabolism reflected induction of apoptosis, we examinedsearched for activating mutations in leukemic blasts from such
patients. A previous study demonstrated that the FLT3 internal the amount of Annexin V staining 24 hr after treatment with
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Figure 1. FLT3 phosphorylation and IL3 dependence of Ba/F3 cells expressing wild-type or mutant FLT3
A: Immunoblot analysis of parental Ba/F3 cells, Ba/F3 cells infected with a control virus, and Ba/F3 cells expressing wild-type-FLT3, D835Y-FLT3, and 836-
FLT3. Immunoprecipitation of FLT3 was performed with an anti-FLT3 antibody and immunoblots were probed with either anti-FLT3 or anti-phosphotyrosine
antibody 4G10.
B: Growth of Ba/F3 cells expressing WT-FLT3, D835Y-FLT3, and 836-FLT3 after removal of IL3 from the medium. 1  106 cells were plated in medium
without IL3 on day 0, and the number of cells counted on the indicated days.
PKC412. Greater than 70% of the cells expressing D835Y-FLT3 four of the five cell lines tested expressed detectable levels of
and 836-FLT3 growing in the absence of IL3 were Annexin V FLT3, with the SEMK2-M1 line having the highest expression
positive (Figure 2C). Conversely, after treatment with PKC412, level (Figure 3). This was confirmed by flow cytometric analysis
only 15%–20% of the cells were positive for Annexin V staining for cell surface expression (data not shown). Next, we deter-
when grown in the presence of IL3 (Figure 2C). Furthermore, the mined the phosphotyrosine content of FLT3. As expected the
tyrosine phosphorylation of the mutated FLT3 was significantly MV4;11 cell line containing a FLT3-ITD showed high level FLT3
inhibited by treatment with PKC412 (Figure 2D). Thus, PKC412 tyrosine phosphorylation. Interestingly, the SEMK2-M1 line,
induces apoptosis in cells that are dependent upon activated which has extremely high level FLT3 expression, also has high
FLT3 for their survival, and it does not affect cells dependent levels of phosphorylated FLT3. The other lymphoblastic leuke-
upon an alternative signal such as IL3. Also, PKC412 inhibits the mia lines showed minimal or no phosphorylated FLT3 (Figure 3).
newly described 836 mutation, and therefore appears active Since SEMK2-M1 expresses high levels of active FLT3, we
against all FLT3 mutations identified in MLL. examined the mechanism by which FLT3 is activated. First,
we sequenced the entire coding region of FLT3 and found no
mutations. Next we tested for amplification of the FLT3 locusPKC412 is cytotoxic to MLL cells that contain
in SEMK2-M1 using fluorescence in situ hybridization (FISH).mutant or wild-type FLT3
BAC FISH probes spanning the FLT3 locus demonstrated FLT3As MLL is characteristically a chemo-resistant leukemia, we
amplification in SEMK2-M1 (Figure 4A), whereas FLT3 amplifi-were particularly interested in determining if FLT3 inhibitors
cation was not demonstrated in MV4;11 and RS4;11 (Figuresmight prove effective in this leukemia. In order to determine if
4B and 4C). The SEMK2-M1 FLT3 amplification was intrachro-FLT3 inhibition induces apoptosis in MLL cells, we assessed
mosomal, with each amplicon containing approximately tenthe ability of PKC412 to induce death in five different ALL or
copies of the FLT3 locus. One or two amplicons, integrated intoAML cell lines. Two of the cell lines, RS4;11 and SEMK2-M1,
the short arm of chromosome 7, were found in all SEMK2-M1are derived from patients diagnosed with B-precursor lympho-
cells (Figure 4A). Activation of FLT3 in these leukemia cell linesblastic leukemia. Both cell lines contain a t(4;11) involving the
can be associated with high level expression of the wild-typeMLL gene and are thus referred to as MLL cell lines (Greil et
receptor secondary to amplification of the genomic locus asal., 1994; Pocock et al., 1995; Stong et al., 1985). The cell lines
found in SEMK2-M1 as well as mutation.Blin1 and UoC-B1 are derived from patients with B-precursor
We next assessed whether high level FLT3 activity wouldlymphoblastic leukemia and do not contain MLL rearrangements
predict sensitivity to FLT3 inhibitors in MLL. Thus, we examined(Inaba et al., 1992; Wormann et al., 1989). MV4;11 is an AML
if inhibition of FLT3 by PKC412 led to cytotoxicity in the leukemiacell line with an MLL rearrangement that was recently demon-
cell lines. Increasing concentrations of PKC412 were incubatedstrated to posses a FLT3-ITD (Levis et al., 2002).
with each of the cell lines, and the percentage of metabolicallyFirst we determined the relative expression levels and the
active cells determined by MTT assay 48 hours after additionrelative activity of FLT3 by assessment of its phosphotyrosine
of the inhibitor. MV4;11 and SEMK2-M1 were particularly sensi-content. FLT3 is known to be expressed in most leukemia cell
lines (DaSilva et al., 1994; Meierhoff et al., 1995). As expected, tive to the PKC412 (Figure 5A). We then determined if the effects
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Figure 2. PKC412 sensitivity of Ba/F3 cells dependent upon FLT3 for survival
A: MTT assay performed 48 hr after addition of PKC412 at the indicated concentration to Ba/F3 cells expressing D835Y-FLT3 growing in the absence ()
or presence () of IL3, and Ba/F3 cells expressing wt-FLT3 growing in the presence of IL3 (). Y axis is the absorbance reading for PKC412-treated cells
divided by DMSO-treated cells. Error bars are from triplicate experiments.
B: Ba/F3 cells expressing 836-FLT3 growing in the absence () or presence () of IL3, and Ba/F3 cells expressing wt-FLT3 growing in the presence of
IL3 ().
C: Percentage of cells that stain positive for Annexin V as assessed by flow cytometry 24 hr after the addition of 100 nM PKC412. Ba/F3 cells expressing
D835Y-FLT3 and 836-FLT3 were grown in the absence of IL3 and treated with PKC412 (IL3). Simultaneously, the same cell line was treated with PKC412
after the re-addition of IL3 (IL3). The experiment was repeated two times with similar results.
D: Immunoprecipitation of FLT3 from cells expressing D835Y-FLT3 or 836-FLT3 after treatment for 4 hr with the indicated amount of PKC412. Immunoblots
were then probed with either anti-FLT3 or anti-Phosphotyrosine antibodies.
seen in the MTT assay were due to an induction of apoptosis type FLT3. Increasing concentrations of PKC412 were incu-
bated with lymphoblasts, and an MTT assay was performed atby PKC412. Approximately 50% of the SEMK2-M1 and MV4;11
cells were positive for Annexin V staining whereas there was 48 hr. Three of four MLL samples were sensitive to treatment
with PKC412 whereas none of the other leukemia samples weremuch less staining of RS4;11, UoC-B1, and Blin1 at 24 hr (Figure
5B). Finally, treatment with PKC412 inhibited receptor phos- affected (Figure 5D). The samples possessing t(4;11) and wild-
type FLT3 were as sensitive as the one with t(4;11) and a 836phorylation in SEMK2-M1 and MV4;11 (Figure 5C). Thus
mutation. Thus it appears that PKC412 may be effective againstPKC412, an inhibitor of FLT3, induces cell death in MLL-
MLL samples with either high level expression of wild-type orrearranged leukemia cell lines with activated FLT3.
mutant FLT3.Since PKC412 is differentially cytotoxic to MLL cell lines,
we determined the effect of PKC412 on primary patient
lymphoblasts. We tested lymphoblasts from seven patients that PKC412 is active against MLL in vivo
We next asked if PKC412 would prove effective against an inpossess various genetic abnormalities, four of which were MLL
lymphoblasts. Of the four MLL samples, all are known to have vivo model of MLL. We established a xenograft model system
in which leukemia burden could be quantitated with in vivohigh level expression of FLT3 (Armstrong et al., 2002). One
sample harbored the 836 mutation and the others had wild- bioluminescent imaging. SEMK2-M1 and RS4;11 cell lines were
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analysis of similarly xenografted mice confirmed that the leuke-
mia cells were initially found in the mouse bone marrow present
in the femoral head (data not shown). The leukemia subse-
quently progressed to replace the normal bone marrow and
involve other organs, thus mimicking the progression of human
leukemia. Once the leukemia had engrafted, as determined by
the presence of a bioluminescent signal (Figure 6A), we treated
a cohort of mice with either 150 mg/kg PKC412 or vehicle once
daily via gavage for 5 days per week. We then performed serial
imaging of the two cohorts to quantitate disease burden (Figure
6A). In mice engrafted with SEMK2-M1 cells, quantification of
total leukemic burden revealed anti-tumor efficacy of PKC412
after 2 weeks of therapy (Figures 6A and 6B). The anti-tumor
effect of PKC412 was specific for the cell line with activated
FLT3 (SEMK2-M1) as it had no effect on leukemia produced by
injection of the cell line RS;411(Figure 6C). Pathological analysis
performed at the completion of the study confirmed the vast
differences in tumor burden in SEMK2-M1 injected mice treated
with PKC412 as compared to control mice (Figure 7). Thus, oral
administration of PKC412 is effective in vivo against human
Figure 3. Expression level and phosphotyrosine content of FLT3 in leukemia lymphoblastic leukemia with an MLL rearrangement and acti-
cell lines
vated FLT3.
FLT3 was immunoprecipitated from 20  106 cells of the indicated cell line.
Immunoblots were then performed with anti-FLT3 and anti-phosphotyrosine
Discussionantibodies. Multiple FLT3 bands on the immunoblot represent differential
glycosylation states.
We describe the validation of a molecular target identified by
gene expression based cancer classification. We have recently
shown that lymphoblastic leukemias with rearrangement of the
engineered to express firefly luciferase fused to neomycin phos- MLL gene on chromosome 11q23 have a gene expression pro-
photransferase by retroviral transduction. One million labeled file that is unique from other leukemias. Based on this, we
leukemia cells were then injected into the tail vein of SCID-beige proposed that they be considered a distinct entity, MLL (Arm-
mice. Within 1 week, the bioluminescent signal was detectable strong et al., 2002). As high level expression of FLT3 was the
gene that best distinguished MLL from other leukemias, wein a location consistent with the femur (Figure 6A). Pathologic
Figure 4. Assessment of FLT3 in leukemia cell lines by FISH
A genomic probe containing the entire FLT3 locus was hybridized to leukemia cells lines SEMK2-M1, MV4;11, and RS4;11. SEMK2-M1 interphase and metaphase
cells (A) have chromosomally integrated FLT3 amplicons, each amplicon containing approximately ten copies of the FLT3 locus. SEMK2-M1 also has one
nonamplified normal FLT3 locus, which is indicated by a white arrow in an interphase cell (top) and metaphase cell (middle). MV4;11 (B) and RS4;11 (C)
cells have two normal copies of the FLT3 locus, with no FLT3 amplification.
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Figure 5. In vitro sensitivity of leukemia cell lines and primary lymphoblasts to PKC412
A: MTT assay performed 48 hr after addition of the indicated amount of PKC412 to MV4;11(), SEMK2-M1 (), RS4;11(), UoC-B1(), and Blin1 () cell lines.
Y axis is the absorbance reading for PKC412-treated cells divided by DMSO-treated cells. Error bars are from triplicate experiments.
B: Percentage of cells that stain positive for Annexin V as assessed by flow cytometry 24 hr after addition of 500 nM PKC412. Error bars are from three
independent experiments.
C: Immunoprecipitation analysis of FLT3 from MV4;11 and SEMK2-M1 cells 4 hr after treatment with the indicated concentration of PKC412. Immunoblots
were probed with anti-FLT3 to assess FLT3 loading and anti-phosphotyrosine (4G10) to assess for phosphotyrosine content of FLT3.
D: MTT assay performed 48 hr after addition of PKC412 to primary lymphoblasts from four patients with MLL (,,,) and three patients with other types
of lymphoblastic leukemias (,,). The genetic characteristics of the leukemias are indicated at the right.
hypothesized that inhibition of FLT3 might be a new therapeutic identify new molecular targets. Multiple studies have shown that
gene expression patterns can be used to identify prognosticavenue in this disease. The data presented here supports this
hypothesis in that up to 16% of MLL specimens contain activat- subsets within morphologically similar tumors (Alizadeh et al.,
2000; Pomeroy et al., 2002; Shipp et al., 2002; Yeoh et al.,ing FLT3 mutations. Cell lines with MLL rearrangements and
activated FLT3 appear to be dependent on it, displaying exqui- 2002). While expression studies might be predicted to reveal
new therapeutic targets, in practice it has been difficult to selectsite sensitivity to inhibition of FLT3. Primary MLL patient sam-
ples are also sensitive to the FLT3 inhibitor PKC412. Further- the valid targets from the multitude of differentially expressed
genes. For example, a substantial portion of differentially ex-more, a xenograft mouse model of MLL leukemia is effectively
treated with a small molecule inhibitor of FLT3. pressed genes between leukemias appear to reflect differences
in lineage or stage of differentiation (Ferrando et al., 2002). SolidJustifying FLT3 as a therapeutic target for MLL has helped
credential the utility of differential gene expression patterns to tumors will also likely be plagued by this issue compounded by
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Figure 6. In vivo bioluminescent imaging of mice injected with SEMK2-M1 leukemia cells
A: SCID-beige mice were injected with 1  106 SEMK2-M1 leukemia cells that have stable luciferase expression. One week after injection, engraftment of
the leukemia cells was confirmed and mice were treated with either 150 mg/kg PKC412 or vehicle 5 of 7 days per week. Week 0 denotes start of therapy.
Mice were imaged weekly to assess for leukemia progression.
B and C: SCID-beige mice were injected with 1  106 SEMK2-M1 (B) or RS 4;11 cells (C), and the amount of bioluminescence was quantitated (photonic
flux) weekly. Mice were treated with either 150 m/kg PKC412 () or vehicle () for 5 days per week. Week 0 denotes the time at which the mice began
therapy. Therapy began 1 week after injection of leukemia cells.
the presence of infiltrating inflammatory and stromal cells. Given FLT3 mutations were believed to be rare in lymphoblastic leuke-
mias. The finding that FLT3 is mutated in MLL illustrates thethis variability, it is a daunting task to predict which genes
actually participate in the oncogenic process. Therefore, an power of correlating gene expression analysis with a genomic
defect involved in the genesis of the tumor to rank potentialapproach is needed to focus attention on the most likely candi-
dates. We reasoned that genes whose expression most strictly targets. Validating FLT3 as a therapeutic target has outlined
one avenue to the identification of new molecular targets. Whilecorrelated with distinct genetic subtypes of leukemia might
prove attractive targets. We therefore analyzed FLT3, which recurrent chromosomal translocations are not characteristic of
most solid tumors, other events including deletions and amplifi-shows consistently high level expression in MLL even though
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Figure 7. Histopathology of mice injected with SEMK2-M1 at the end of three weeks of treatment with either PKC412 or control
H&E stained liver sections from mice after 3 weeks of treatment with PKC412 or vehicle control. Images were taken at either 4 or 60 magnification.
cations that are being quantified by approaches such as array or proliferation signal that results in expansion of the neoplastic
cells. A constitutively active FLT3 represents an attractive candi-comparative genomic hybridization (array CGH) may serve the
same purpose. date for a “second hit” necessary for the development of MLL
while other tyrosine kinases or downstream genes in the FLT3The application of genomic technologies will increase the
number of potential molecular targets leading to an expectation pathway are also likely candidates. Along these lines, a recent
study has shown that the receptor tyrosine kinase v-Sea canthat validating targets will become a rate-limiting step in translat-
ing these opportunities into new therapies. More rapid methods cooperate with an MLL fusion protein to produce leukemia in
an avian system (Schulte et al., 2002). Findings here warrantof small molecule discovery combined with improved animal
models of human disease should help speed the process of drug exploring the mechanisms of complementation between tyro-
sine kinases such as FLT3 and leukemogenic fusion proteins.development. While conventional xenograft models of human
disease have been useful, they are limited by the inability to Patients with MLL harboring activating mutations of FLT3
should be considered candidates for therapy with FLT3 inhibi-accurately follow tumor progression unless the tumor is injected
subcutaneously. Here we have used in vivo bioluminescent im- tors. It is also conceivable that overexpression of a wild-type
receptor might qualify as a candidate. The SEMK2-M1 cell line,aging to follow leukemia progression. In this model system, the
leukemia develops in the bone marrow and progresses to more which has amplified the FLT3 locus, displays an extremely high
level of activated wild-type receptor, and its treatment withdisseminated disease much like that of human leukemia. The
ability to follow tumors growing in their natural milieu represents PKC412 shows efficacy both in vitro and in vivo. Of note, primary
lymphoblasts with high level expression of wild-type FLT3 werea model that should prove more predictive of the behavior of
human disease. Also, the use of bioluminescent imaging allowed also sensitive to PKC412. Preliminary examination indicates that
FLT3 amplification is not universal in primary MLL samples (notus to determine the efficacy of PKC412 within 3 weeks, a sig-
nificantly shorter period than if we had used the standard mea- shown). However, high level expression of a wild-type FLT3
receptor in MLL appears to confer dependence. As FLT3 issure of mouse survival as an endpoint. Advances in in vivo
imaging coupled with xenograft and genetically engineered consistently highly expressed in MLL (Armstrong et al., 2002),
perhaps all MLL cases deserve to be tested for response tomouse models of cancer constitute critical resources for target
validation and drug development. FLT3 inhibitors. Further studies with FLT3 inhibitors may identify
a threshold level of FLT3 activity that confers dependence onThe presence of activating FLT3 mutations in MLL is in
keeping with a multistep pathway to leukemogenesis (Gilliland this pathway. Support for this vantage point is provided by
studies of c-KIT in gastrointestinal stromal tumors where highand Griffin, 2002). In this model, MLL fusion proteins are hypoth-
esized to lead to an inappropriate developmental decision that level expression of the wild-type receptor, as well as receptor
mutation, lead to constitutive signal propagation (Rubin et al.,is necessary, but not sufficient to induce leukemia. Within this
hematopoietic progenitor, a second mutation provides a survival 2001). Similarly, high level expression of the wild-type ERBB-2
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Patient leukemia samplesreceptor leads to constitutive activation of this pathway in breast
Patient samples were obtained from peripheral blood or bone marrow fromcancer (Di Fiore et al., 1987; Slamon et al., 1987). Further study
children diagnosed with CD19 B-precursor ALL and determined by eitherof the signaling cascades initiated by wild-type and mutant
cytogenetic analysis, fluorescence in situ hybridization (FISH), or Southern
tyrosine kinase receptors should shed light on this subject, as blot to possess an MLL translocation as described (Cuthbert et al., 2000;
should clinical trials testing the efficacy of FLT3 inhibitors in Silverman et al., 1997).
MLL.
FLT3 expression in Ba/F3 cellsThe data here prompt the development of clinical trials that
The FLT3 cDNA encoding the wild-type FLT3 with a leader peptide fromtest the efficacy of FLT3 inhibitors in MLL. Recent studies indi-
the C-FMS receptor was cloned into an MSCV-based retroviral vector con-
cate FLT3 may be a therapeutic target in AML where up to 30% taining a puromycin resistance cassette (Hawley et al., 1994). Mutant FLT3
of cases contain activating mutations of FLT3 (Gilliland and cDNAs were constructed by PCR amplification of the region surrounding
D835 from mutant patient samples. The PCR product was then used toGriffin, 2002). Several FLT3 inhibitors have been described, and
replace the wild-type sequence. All PCR products were sequenced to assureclinical trials in adult AML are underway. These studies should
the desired mutation and the absence of other mutations. The MSCV-FLT3-provide important data about the efficacy and toxicity of FLT3
WT, MSCV-FLT3-D835Y, and MSCV-FLT3-836 plasmids were then co-
inhibition. Of note, a study evaluating the toxicity of the FLT3 transfected into human embryonic kidney 293 cells with vectors encoding
inhibitor used in this study (PKC412) in patients with solid tumors retroviral gag-pol and env proteins as described (Lessnick et al., 2002). The
has been reported and the side effects were mild (Propper et al., resulting retroviruses were used to introduce FLT3 into Ba/F3 cells, and the
infected cells were selected with puromycin in the presence of IL3. The cells2001). Since tyrosine kinase inhibitors are not always uniformly
surviving selection (70% survival) were then used for experiments. All Ba/effective against all mutations of a given target kinase, it will be
F3 cells expressing wild-type or mutant FLT3 were passaged in puromycinimportant to determine the capability of each molecule to inhibit
and IL3.
the various FLT3 mutations.
Landmark clinical studies have demonstrated success with Reverse transcription-polymerase chain reaction
Total RNA was extracted from cells with Trizol (Invitrogen) and reversetargeted cancer therapy. Perhaps the most celebrated have
transcribed using RETROscript kit from Ambion (Austin, Texas). The resultingbeen trials using therapies that target oncogenes involved in
complementary DNA (cDNA) was used as a template for polymerase chaintumorogenesis. The inhibition of the kinase activity of the BCR-
reaction (PCR) with primers to amplify the region in exon 20 of FLT3 as
ABL fusion protein by the small molecule STI571 (Gleevec) has previously described (Yamamoto et al., 2001). PCR products were digested
produced remissions in chronic myelogenous leukemia (CML) with EcoRV to detect mutations. Any PCR product that was not completely
and acute leukemias with t(9;22) (Druker et al., 2001a, 2001b). digested was then sequenced to confirm the presence of a mutation.
Similarly, inhibition of the receptor tyrosine kinase c-KIT in gas-
Immunoprecipitation and immunoblottingtrointestinal stromal tumors by STI571 has been particularly
Cells were washed with ice-cold PBS and lysed with buffer containing 20effective against this chemotherapy resistant tumor (Demetri et
mM Tris-Cl (pH 7.4), 150 mM NaCl, 100 mM NaF, 10 mM EDTA, 10%
al., 2002). Finally, treatment of breast carcinoma with a mono- glycerol, 1% NP-40, 1 mM phenylmethylsulfonylfluoride, 1 mM sodium or-
clonal antibody targeting the ERBB-2 receptor (Herceptin) im- thovanadate, and 100 U/mL leupeptin. Cell extracts were subjected to immu-
proved chemotherapy response and prolonged survival (Slamon noprecipitation and immunoblotting with the antibodies indicated.
Samples were separated by 4%–12% Bis-Tris-polyacrylamide gel elec-et al., 2001). FLT3 inhibition in MLL represents an important
trophoresis and transferred to nitrocellulose membranes (Schleicher &opportunity in this particularly chemotherapy resistant leukemia.
Schuell Inc., Keene, New Hampshire). Western blots were probed with anti-
bodies indicated. Blots were then labeled with anti-rabbit, anti-goat, or anti-Experimental procedures
mouse IgG-HRP antibody (Vector Laboratories, Burlingame, California) and
visualized using ChemiLuminescence Reagent Plus (Perkin-Elmer, Boston,Reagents
Massachusetts).The rabbit polyclonal anti-FLT3 antibody Sc479 was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, California). The goat polyclonal anti-
Apoptosis and MTT assaysFLT3 antibody AF812 was purchased from R&D Systems (Minneapolis, Min-
MTT assays were performed using the manufacturer’s recommendationsnesota). Monoclonal antibody 4G10 was obtained from Upstate Biotechnol-
(Roche, Indianapolis, Indiana). Briefly, 1  105 cells were plated in 100
ogy (Lake Placid, New York). Recombinant preparations of murine IL-3 were
microliters of medium in 96 well microtiter plates with the indicated concen-
obtained from R&D Systems. Restriction enzymes were from New England
tration of PKC412. The cells were then incubated for 48 hr. Ten microliters
Biolabs Inc. (Beverly, Massachusetts). PKC412 was obtained from Novartis
of labeling reagent was added to each well and allowed to incubate at 37
Pharma AG, Basel, Switzerland and dissolved in DMSO to make a stock
for 4 hr. The precipitate was then solubilized overnight and assessed by an
solution from which further dilutions were made. ELISA reader. Annexin V staining was assessed by flow cytometry using the
manufacturer’s recommendations (Biovision, Mountain View, California) 24
Cell lines and cell culture hr after the addition of the indicated amount of PKC412.
All cell culture reagents were obtained from Invitrogen (Rockville, Maryland).
All cells were cultured in the appropriate medium in a humidified incubator FISH analysis of leukemia cell lines
at 37C in 5% CO2. Medium was supplemented with penicillin/streptomycin BAC (RP11-153M24 and RP11-179F17) genomic DNA clones spanning the
and L-glutamine. All leukemia cell lines were grown in RPMI 1640 with 10% FLT3 locus were isolated and labeled as previously described (Hibbard et
FCS. Ba/F3 cells were grown in RPMI 1640 with 10% FCS supplemented al., 2000). Probe detection was with Texas Red-streptavidin (Zymed Labora-
with 10 ng/ml recombinant IL-3 (R&D Systems). RS4;11, UoC-B1, and Blin1 tories, San Francisco, California). In order to determine the number of copies
are previously described and well-characterized leukemia cell lines (Inaba of the FLT3 locus, individual FISH signals were counted in multiple nuclei
et al., 1992; Stong et al., 1985; Wormann et al., 1989). The SEMK2-M1 cell from interphase cells.
line is a subclone of the previously described lymphoblastic leukemia cell
line SEMK2 (Pocock et al., 1995). This line was originally derived from Mouse studies and in vivo imaging
lymphoblasts of a 5-year-old girl in first relapse with a t(4;11) positive ALL The coding region of the firefly luciferase gene from pGL3-basic (Promega)
(Greil et al., 1994). Human embryonic kidney (HEK293) were grown in Dulbec- and the coding region of neomycin phosophotransferase from pEGFP-N3
(Clontech) were amplified with high-fidelity polymerase (Platinum Pfx, In-co’s Modified Eagle Medium supplemented with 10% FCS.
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(1994). Expression of the FLT3 gene in human leukemia-lymphoma cell lines.vitrogen) and fused in frame in the pMMP retrovirus (courtesy Richard Mulli-
Leukemia 8, 885–888.gan, HHMI, Boston, Massachusetts) to create pMMP-LucNeo. VSV-G pseu-
dotyped retroviruses were packaged by cotransfection with expression Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisen-
vectors encoding packaging functions (pMD-G and pMD-MLV, courtesy berg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek,
Richard Mulligan) in 293T cells. Retroviruses were concentrated, stored M., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastro-
frozen, titered, and verified to be free of replication-competent viruses as intestinal stromal tumors. N. Engl. J. Med. 347, 472–480.
previously described (Burns et al., 1993). Cells were transduced with retrovi-
Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., and Aaron-rus utilizing Retronectin (Takara) according to manufacturer’s instructions,
son, S.A. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/and subsequently selected in medium containing G418 1 mg/ml (Invitrogen).
3T3 cells. Science 237, 178–182.One million luciferase-expressing cells were intravenously injected via the
tail vein into SCID-beige mice (Taconic). Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M.,
For imaging, mice were anesthetized with an intraperitoneal injection Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers,
C.L. (2001a). Efficacy and safety of a specific inhibitor of the BCR-ABLof ketamine hydrochloride 150 mg/kg and xylazine 12 mg/kg (Webster).
tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–D-luciferin 50 mg/kg (Xenogen) was concomitantly administered by intraperi-
1037.toneal injection. Photonic emission was imaged using the In Vivo Imaging
System (IVIS, Xenogen) with total imaging time of 2 min. Total body biolumi- Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford,
nescence was quantified by integrating the photonic flux (photons/sec) J.M., Capdeville, R., and Talpaz, M. (2001b). Activity of a specific inhibitor
through a region of interest drawn around each mouse. PKC-412 (Novartis) of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia
or vehicle control were formulated and administered by oral gavage as and acute lymphoblastic leukemia with the Philadelphia chromosome. N.
previously described (Weisberg et al., 2002). Engl. J. Med. 344, 1038–1042.
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